High Resolution Size Exclusion Chromatography Analysis of Small Therapeutic Proteins

Significance of the Topic

Size exclusion chromatography (SEC) is essential for evaluating the purity and aggregation state of small therapeutic proteins such as human growth hormone, granulocyte colony-stimulating factor, and interferon α-2b. Aggregation can impair drug stability and efficacy, making high-resolution SEC a critical quality control tool in biopharmaceutical development and manufacturing.

Objectives and Study Overview

This study compares the performance of Agilent AdvanceBio SEC 120 Å 1.9 µm columns against competing sub-2 µm SEC columns. Key goals include assessing resolution, peak shape, and reproducibility for three model proteins, and establishing optimized methods for detecting monomer, dimer, and higher or lower molecular weight species.

Methodology and Instrumentation

All analyses employed an Agilent 1260 Infinity II Bio-inert liquid chromatography system. The column used was AdvanceBio SEC 1.9 µm 120 Å (4.6 × 300 mm). Mobile phase consisted of sodium phosphate buffer (pH 7.0) with varying NaCl concentrations for optimization. Flow rates of 0.30–0.35 mL/min, column temperature of 25 °C, and 2 µL injections at 1 mg/mL were applied. Calibration standards spanned 244 Da to 44 kDa. Samples included recombinant hGH, hG-CSF, and interferon α-2b, including thermally stressed material.

Results and Discussion

The AdvanceBio SEC column exhibited a linear calibration curve over the 1–80 kDa range, enabling accurate estimation of unknowns. In hG-CSF separations, clear baseline resolution of monomer and dimer peaks was achieved with minimal tailing and superior USP resolution compared to competitor columns. Analysis of somatropin revealed distinct HMW aggregate detection. For interferon α-2b, method optimization identified 200 mM phosphate with 250 mM NaCl at pH 6.5 as optimal for narrow peaks (peak width 0.14 min) and high resolution of HMW-monomer and monomer-LMW species. Across all tests, AdvanceBio SEC delivered the sharpest peaks and highest reproducibility.

Benefits and Practical Applications

• Enhanced detection of protein aggregates and impurities in drug products
• Improved method reproducibility and early problem identification through routine calibration
• Applicability to a range of small biotherapeutics with similar molecular weights
• Shorter run times and higher throughput for QC and stability studies

Future Trends and Opportunities

Advancements in SEC are expected to include novel stationary phase coatings for deeper suppression of secondary interactions, integration with mass spectrometry for enhanced detection sensitivity, online bioprocess monitoring, and developments in miniaturized UHPLC and nano-SEC platforms to reduce sample and solvent consumption.

Conclusion

The Agilent AdvanceBio SEC 120 Å 1.9 µm column outperforms comparable sub-2 µm technologies in resolving small protein therapeutics. Routine calibration and optimized mobile phase conditions ensure reliable purity assessment and aggregation profiling, contributing to more efficient biopharmaceutical quality control.

References

1. Bayol A et al. Pharmeuropa Bio, 2004, 2004(1):35–45.
2. Advani SH et al. Indian Journal of Medical and Paediatric Oncology, 2010, 31(3):79–82.
3. Sharma VK, Kalonia DS. Pharmaceutical Research, 2003, 20:1721–1729.
4. Johnston MJW et al. Pharmaceutical Research, 2011, 28:1661–1667.